Can a better scan sharpen radiation for prostate cancer?

NCT ID NCT03762759

Ongoing Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether two different PET/CT tracers—fluciclovine F18 and 68Ga-PSMA—can better guide radiation therapy planning for men with prostate cancer who have a rising PSA after surgery. The goal is to see if one tracer more accurately spots remaining cancer cells, allowing doctors to target radiation more precisely and improve disease-free survival. About 140 participants will be randomly assigned to one of the two tracers, and their outcomes will be compared.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Two radiotracers for PET/CT imaging: fluciclovine F18 and gallium Ga68-labeled PSMA-11
What this could lead to: If one tracer proves better at spotting residual cancer, it could lead to more precise radiation planning and improved disease-free survival for men after prostate surgery.
What could go wrong: This is a phase 2 trial, so results are preliminary. The tracers may not differ in effectiveness, and imaging accuracy can vary. Radiation therapy carries risks like urinary or bowel side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Grady Health System

Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.